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Abstract: Increasing evidence links genomic and epigenomic instability, including multiple fragile sites regions to neuro-
psychiatric diseases including schizophrenia and autism. Cancer is the only other disease associated with multiple fragile 
site regions, and genome and epigenomic instability is a characteristic of cancer. Research on cancer is far more advanced 
than research on neuropsychiatric disease; hence, insight into neuropsychiatric disease may be derived from cancer re-
search results. Towards this end, this article will review the evidence linking schizophrenia and other neuropsychiatric 
diseases (especially autism) to genomic and epigenomic instability, and fragile sites. The results of studies on genetic, 
epigenetic and environmental components of schizophrenia and autism point to the importance of the folate-methionine-
transulfuration metabolic hub that is diseases also perturbed in cancer. The idea that the folate-methionine-transulfuration 
hub is important in neuropsychiatric is exciting because this hub present novel targets for drug development, suggests 
some drugs used in cancer may be useful in neuropsychiatric disease, and raises the possibility that nutrition interventions 
may influence the severity, presentation, or dynamics of disease. 
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INTRODUCTION 
  Genomic instability refers to an increased mutation rate 
that can take the form of chromosomal abnormalities, 
translocations, large or small insertions or deletions and base 
changes. Epigenomic instability refers to perturbed re-
sponses of gene regulation to environmental fluctuations. 
Fragile site regions of the genome have high levels of ge-
netic and epigenetic instability. 
  In 2003, we reported a link between somatic mutations 
(genomic instability) and fragile sites and schizophrenia [1]. 
Later, we reported aberrant epigenetic regulation of genes 
involved in dopamine metabolism in the synaptic cleft in 
schizophrenia and bipolar disease brains [2, 3]. Today, there 
is increasing evidence for genome instability in neuropsy-
chiatric diseases, including an association with fragile site 
regions. Cancer is the only other disease associated with 
multiple fragile site regions, and genome instability is a 
characteristic of cancer. This article will review the evidence 
linking schizophrenia and other neuropsychiatric diseases 
(especially autism) to genomic and epigenomic instability 
and fragile sites.  
Schizophrenia and Autism 
  Schizophrenia and Autism are neuropsychiatric diseases 
linked to multiple genetic and environmental factors. Like  
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many common illnesses these diseases remain an enigma 
because there is no single factor or small number of factors 
that accounts for a large number of patients.  
  The prevalence of schizophrenia is ~1% worldwide but 
varies between 0.3 to 2.7% [4]. Diagnosis is based on the 
appearance and duration of about 30 symptoms divided into 
positive (e. g. hallucinations (especially auditory are com- 
mon)), negative (e.g. withdrawal, blunted affect etc), and 
cognitive (executive function). However, symptoms (endo- 
phenotypes) and outcome (Fig. 1) vary even in the same 
family, raising the possibility that several different diseases 
(i. e. the “schizophrenias”) presenting similar collections of 
symptoms have been grouped together [5, 6]. These and 
other observations suggest that a genetic predisposition is not 
sufficient by itself to cause disease. Further in some cases, 
the disease appears to be environmentally induced in the 
absence of detectable genetic predisposition (see below). 
  Autism is a complex, early onset (typically <5 years of 
age) lifelong illness that is difficult to diagnose and treat. 
Autism appears to be multiple diseases that make up autism 
spectrum disorder (ASD) defined by limits in three behaviors 
(1) social interactions, (2) communication and imaginative 
play, and (3) interests and activities. Other symptoms include 
impaired immunological responses, inflammation (especially 
in the gut), and oxidative stress [7]. Today, treatments in-
clude intensive educational and behavioral interventions with 
drugs to reduce remaining symptoms.  
GENETICS 
  First-degree relatives of schizophrenia probands have a 
~10% probability of becoming ill [8], while ~ 50% of cases 448    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
of schizophrenia are spontaneous with no other affected fam-
ily member [9]. Although variable [10-12], the general belief 
is that ~50% of monozygotic twins afflicted with schizo-
phrenia are discordant for the disease, although progeny of 
both the well and ill discordant MZ twin have the elevated 
probably (~10%) typical of first degree relatives of ill indi-
viduals [13]. 
  Genetic studies have linked many genes and chromoso-
mal regions spread throughout the genome to schizophrenia 
in different families, but no single or small number of genes 
accounts for the majority of cases. Common alleles have 
small effects (e. g. ZNF804) while rare alleles (e. g. NRG1, 
DTNB1, DAOA and DISC1) have greater effects [14]. A 
summary of the genes linked to schizophrenia is shown in 
Table 1. Genes linked to schizophrenia do not affect a single 
neurobiological system, and include neurotrophic factors (e. 
g. BDNF, NRG), neuromodulatory receptors (DRD, HTR), 
members of the synaptic packaging and release machinery 
(SNAP25), and both inhibitory and excitatory neurotransmit-
ter systems (GRIN, GRIK, GABR). Also, there are genes 
linked to folate processing (MTHFR) and methylation (e.g. 
DNMT, COMT) see below.  
  Except for mitochondrial defects in a subset of patients, no 
other common genetic or environmental factor, nor is an effec-
tive intervention linked to a majority of patients [15]. 
Clearly, there a genetic component with multiple genes 
linked to the disease (for reviews see [16] and [17]). Many 
genes linked to autism are similar to those linked to schizo-
phrenia and bipolar disorder ([18, 19], http://neuropsych.bu. 
edu).  
EPIGENETICS 
  Epigenetic programming refers to factors that are “epi”, 
or "on top of" genetic (DNA) sequences and was coined by 
Waddington in the 1940s to link genes and development [20] 
(Fig.  2). Epigenetic regulation allows a single genome to 
code for functionally different cell types and short-term ad-
aptation (for reviews see references [21-25]). In contrast, 
DNA sequence changes are responsible for long-term adap-
tation and evolution.  
  The term “epigenetic programming” is evolving, and 
today refers to reversible molecular changes to DNA, RNA 
or proteins (e. g. histones) that regulate gene function but do 
not involve DNA base changes. Epigenetic changes include 
DNA methylation, RNA modification (e.g. editing (addi-
tion/deletion/change to base sequence), RNA interference) 
and both histone and non-histone proteins modifications (e. 
g. methylation, acetylation, phosphorylation, sumoylation, 
ubiquitination). 
  Epigenetic programming of chromatin begins shortly 
after DNA synthesis, although subsequent alterations may 
occur in response to variety of ordinary or pathological envi-
ronmental or biological factors. Epigenetic changes occur 
globally early in development, and at specific loci through-
out life and in disease states [26-28]. In cancer, the impact of 
epigenetic modification on gene expression has been studied 
for some time [29-35].  
DNA Methylation 
  DNA methylation is the best-characterized epigenetic 
factor controlling gene expression (Fig. 3; for reviews see 
[24, 25, 36-38]). In vertebrates, 4-8% of all cytosines, and 
70% of cytosines within the 5'CpG3' dinucleotide sequence, 
are methylated. In contrast, 70% of the cytosines at 5'CpG3' 
dinucleotide sequences within promoter regions of active 
genes are unmethylated. There are ~29,000 "CpG islands" 
(regions rich in 5'CpGs3') in the human genome 2 sequence. 
The methylation state of half of these islands regulates 
mRNA expression. About half of these islands are highly 
methylated [39]. DNA methyltransferase (DNMT) enzymes 
are responsible for methylation of CpG sequences [40], with 
the rate of methylation determined by the availability of 
DNMTs and their relative affinity for a given CpG site on 
DNA [41], and other co-factors (see below). Today, no DNA 
demethylase has been identified.  
  The number and location of methylated CpG sites in 
promoter regions usually, but  not always, correlates with 
gene expression in vivo [24, 25, 36, 37, 38, 42]. Usually, 
dense DNA methylation is associated with irreversible si-
lencing of gene expression, while a strong activator can 
overcome partial methylation. Partial promoter DNA methy-
lation marks genes that may become unmethylated and ex-
pressed, allowing for re-adaptation to a changing micro- or 
macro- environment (e.g. season, ecological conditions, nu-
tritional habits and demands of different developmental peri-
ods (see below)). More complexity in DNA methylation is 
introduced when the state of CpG sites within genes (i.e. 
outside the promoter regions) are compared to promoter 
dinucleotides. Ball et al. [39] show that methylation of CpG 
sites within genes is correlated with light promoter methyla-
tion; hence, gene body methylation appears to correlate with 
expression. 
  DNA methylation in promoter regions occurring at 
5’CpG3’ dinucleotides within transcription factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Classification of schizophrenia based on outcome. The 
outcome of schizophrenia disease is highly variable; suggesting 
different diseases may have been grouped together. (Adapted from 
Summary report of symposium “Schizophrenia and other Psychosis 
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Table 1.  Fragile Sites in the Human Genome 
Chr Locus    Location  R/C Agent 
1 FRA1E  1p21.2 C  Aph 
1 FRA1M  1p21.3 R  FolA 
1 FRA1D  1p22  C  Aph 
1 FRA1L  1p31  C  Aph 
1 FRA1C  1p31.2 C  Aph 
1 FRA1B  1p32  C  Aph 
1 FRA1A  1p36  C  Aph 
1 FRA1J  1q12  C   5-Aza 
1 FRA1F  1q21  C  Aph 
1 FRA1G  1q25.1 C  Aph 
1 FRA1K  1q31  C  Aph 
1 FRA1H  1q42  C   5-Aza 
1 FRA1I  1q44  C  Aph 
2 FRA2L  2p11.2 R    FolA 
2 FRA2E  2p13  C  Aph 
2 FRA2D  2p16.2 C  Aph 
2 FRA2C  2p24.2 C  Aph 
2 FRA2A  2q11.2 R  FolA 
2 FRA2B  2q13  R  FolA 
2 FRA2F  2q21.3 C  Aph 
2 FRA2K  2q22.3 C  Aph 
2 FRA2G  2q31  C  Aph 
2 FRA2H  2q32.1 C  Aph 
2 FRA2I  2q33  C  Aph 
2 FRA2J  2q37.3 C  Aph 
3 FRA3B  3p14.2 C  Aph 
3 FRA3A  3p24.2 C  Aph 
3 FRA3D  3q25  C  Aph 
3 FRA3C  3q27  C  Aph 
4 FRA4D  4p15  C  Aph 
4 FRA4A  4p16.1 C  Aph 
4 FRA4B  4q12  C  BrdU 
4 FRA4E  4q27  C Unclas 
4 FRA4C  4q31.1 C  Aph 
5 FRA5A  5p13  C  BrdU 
5 FRA5E  5p14  C  Aph 
5 FRA5B  5q15  C  BrdU 
5 FRA5D  5q15  C  Aph 
5 FRA5F  5q21  C  Aph 
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(Table 1). Contd….. 
Chr Locus    Location  R/C Agent 
5 FRA5C  5q31.1 C  Aph 
5 FRA5G  5q35  R  FolA 
6 FRA6C  6p22.2 C  Aph 
6 FRA6A  6p23  R  FolA 
6 FRA6B  6p25.1 C  Aph 
6 FRA6D  6q13  C  BrdU 
6 FRA6G  6q15  C  Aph 
6 FRA6F  6q21  C  Aph 
6 FRA6E  6q26  C  Aph 
7 FRA7A  7p11.2 R  FolA 
7 FRA7D  7p13  C  Aph 
7 FRA7C  7p14.2 C  Aph 
7 FRA7B  7p22  C  Aph 
7 FRA7J  7q11  C  Aph 
7 FRA7E  7q21.2 C  Aph 
7 FRA7F  7q22  C  Aph 
7 FRA7G  7q31.2 C  Aph 
7 FRA7H  7q32.3 C  Aph 
7 FRA7I  7q36  C  Aph 
8 FRA8C    8q24.1 C  Aph 
8 FRA8E    8q24.1 R  DistA 
8 FRA8F  8q13  R Unclass 
8 FRA8B  8q22.1 C  Aph 
8 FRA8A  8q22.3 R  FolA 
8 FRA8D  8q24.3 C  Aph 
9 FRA9A    9p21  R  FolA 
9 FRA9C    9p21  C  BrdU 
9 FRA9B    9q32  R  FolA 
9 FRA9E    9q32  C  Aph 
9 FRA9F  9q12  C   5-Aza 
9 FRA9D  9q22.1 C  Aph 
10 FRA10B    10q25.2 R  BrdU 
10 FRA10E    10q25.2 C  Aph 
10 FRA10G  10q11.2  C  Aph 
10 FRA10C  10q21  C  BrdU 
10 FRA10D  10q22.1  C  Aph 
10   FRA10A  10q23.3  R  FolA 
10 FRA10F  10q26.1  C  Aph 
11 FRA11C    11p15.1 C  Aph 
11 FRA11I    11p15.1 R  DistA Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    451 
(Table 1). Contd….. 
Chr Locus    Location  R/C Agent 
11 FRA11E  11p13  C  Aph 
11 FRA11D  11p14.2  C  Aph 
11 FRA11H  11q13  C  Aph 
11   FRA11A  11q13.3  R  FolA 
11 FRA11F  11q14.2  C  Aph 
11   FRA11B  11q23.3  R  FolA 
11 FRA11G  11q23.3  C  Aph 
12 FRA12A  12q13.1  R  FolA 
12 FRA12B  12q21.3  C  Aph 
12 FRA12C  12q24  R  BrdU 
12 FRA12E  12q24  C  Aph 
12 FRA12D  12q24.13 R  FolA 
13 FRA13A  13q13.2  C  Aph 
13 FRA13B  13q21  C  BrdU 
13 FRA13C  13q21.2  C  Aph 
13 FRA13D  13q32  C  Aph 
14 FRA14B  14q23  C  Aph 
14 FRA14C  14q24.1  C  Aph 
15 FRA15A  15q22  C  Aph 
16 FRA16B    16q22.1 R  DistA 
16 FRA16C    16q22.1 C  Aph 
16 FRA16E  16p12.1  R  Aph 
16 FRA16A  16p13.11 R  FolA 
16 FRA16D  16q23.2  C  Aph 
17 FRA17A  17p12  R  DistA 
17 FRA17B  17q23.1  C  Aph 
18 FRA18A  18q12.2  C  Aph 
18 FRA18B  18q21.3  C  Aph 
19 FRA19B  19p13  R  FolA 
19 FRA19A  19q13  C    5-Aza 
20 FRA20A  20p11.23 R  FolA 
20 FRA20B  20p12.2  C  Aph 
22 FRA22B  22q12.2  C  Aph 
22 FRA22A  22q13  R  FolA 
X FRAXB  Xp22.31 C    Aph 
X FRAXC  Xq22.1 C  Aph 
X FRAXD  Xq27.1 C  Aph 
X FRAXA  Xq27.3 R  FolA 
X FRAXE  Xq28  R  FolA 
X FRAXF  Xq28    FolA 
Chr = chromosome number, R/C= Rare or common, Aph=amphidicolin, Fola= Folic acid, 5-Aza= Azacytidine, Data was compiled from [147, 148] and Genome Database. 1999. Chr 
= chromosome; R/C = rare/common, Aph = amphidicolin or folic acid, FolA = Folic Acid; 5-AzaC = 5-Azacytidine, BrdU –Bromo-uridine, Unclass = unclassified, DistA = Distamy-
cin(http://ncbi.nlm.nih.gov).   452    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
recognition sites (e.g. GGGCGG and TGACGTCA for fac-
tors stimulatory protein 1 (SP1) and cAMP response element 
protein (CREB), respectively) may decrease expression of 
genes driven by these factors [25]. Gene activation itself may 
impact local DNA methylation. For instance, transcription 
factor (e.g. SP1) binding may interfere with DNA promoter 
methylation directly [43].  
  Transcription can be inhibited by proteins that bind di-
rectly or indirectly to methylated DNA (see referenced re-
views above). One methylated DNA binding family, consist-
ing of the MeCP2, MBD1, MBD2, MBD3, and MBD4 pro-
teins, has a conserved methyl-binding domain (MBD) and 
binds singly methylated CpG dinucleotides [44]. Another 
repressor family, all containing a zinc-finger motif, consists 
of Kaiso protein, which binds CGCGs, the Kaiso binding 
sequence (KBS; recognition sequence = TCCTGCNA) pro-
tein, and the ZBTB4 and ZBTB38 proteins that bind lone 
methylated CpGs dinucleotides [45]. 
  Epigenetic changes in DNA are correlated with amino 
terminal histone 3 modifications (methylation and acetyla-
tion)(for reviews see [46, 47, 25]; Fig. 3). Promoter regions 
of expressed genes (i.e., unmethylated regions) have histone 
3 lysine-4 methylation (H3K4
me) and histone 3 lysine-9 ace-
tylation (H3K9
ac) modifications. Promoter regions of un-
expressed genes, (i.e. highly methylated regions) have no 
modification at histone 3 lysine 4 (H3K4) but have histone 4 
lysine 9 methylation (H3K9
me).  
  Generally, chromatin codes (DNA and histone) are pre-
served through mitosis, although reprogramming may occur 
[48]. During meiosis and early development, complex differ-
ential global chromatin reprogramming occurs, some spe-
cific for male or female germline and others for develop-
ment. Some germline epigenetic patterns are inherited [48]. 
  Epigenetic programming imprints some genes to be ex-
pression in a parental origin dependent manner [47]. Gene 
imprinting is proven for ~80 genes, and predicted for ~200 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Genetics, epigenetics, and development. Waddington 
[20] coined the term epigenetics linking heritable factors to devel-
opment. He likened development to a ball rolling down a valley, 
with epigenetic changes to DNA (DNA was proven to be the ge-
netic material during this same period of time) directing a single 
genome towards different developmental outcomes, i.e. cell types. 
Epigenetic changes to DNA in a mature cell make development 
into another type of cell difficult (the ball cannot move into another 
valley).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Epigenetic programming to chromatin. DNA methyl transferases (DNMTs) add methyl groups to the cytosines in CpG dinucleo-
tide sequences. Histone 3 lysine 9 methylation (H3K9me) is concurrent with local DNA methylation in promoters. In the absence of pro-
moter DNA methylation, histone 3 lysine 4 methylation (H3K4me) and histone 3 lysine 9 acetylation (H3K9ac) modification are found. Al-
though both the DNA and histone modifications are reversible, only histone de-acetylases (HDAC) and de-methylases are known, no DNA 
de-methylase enzyme has been identified. Adapted from [25]. Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    453 
genes (http://www.geneimprint.com). Most imprinted genes 
are associated with growth and development. In female cells, 
epigenetic changes turn off all gene expression from one X 
chromosome randomly in each cell during early embryo-
genesis [49]. This insures that chromosome X gene expres-
sion levels are similar for female (XX) and male (XY) cells.  
  Although, epigenetic contributions to cancer phenotypes 
have been studied for some time, only recently has this area 
of research begun to impact neurological diseases. We and 
others have previously reviewed [24, 25, 50, 51] the connec-
tion between epigenetic modifications and neurological dis-
ease, including the effect of folic acid (a source of methyl 
groups for epigenetic modifications) metabolism on psy-
chotic symptoms, and the co-morbidity of psychosis with 
diseases clearly linked to epigenetic changes (e. g. schizo-
phrenia, bipolar disease, autism, Rett's and Angelmen's 
/Prader-Willi disease, mental retardation and degeneration 
(see below)). 
GENETIC AND EPIGENETIC REGULATION OF 
DOPAMINE METABOLISM 
  The dopamine hypothesis of schizophrenia arose because 
many anti-psychotic medications used in the treatment of 
schizophrenia are dopamine receptor antagonists. Oxygen 
methylation of dopamine by Catechol-O-Methyl Transferase 
(COMT) appears to be the prominent means of dopamine 
catabolism after synaptic release in brain regions such as the 
prefrontal cortex (reviewed in [52]). The 5’ region of the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Genetic and epigenetic regulation of dopamine metabolism in schizophrenia. (A) Dopamine released by the pre-synaptic neuron 
into the synaptic cleft may dock with dopamine receptors on the post-synaptic neuron for downstream signaling; be degraded by MAO or 
COMT; or be taken back up into the pre-synaptic neuron by binding to DAT. (B) When dopamine degradation is high, for instance, by an 
increase in COMT activity, dopamine receptors expression is elevated to compensate for low amounts of dopamine in the synaptic cleft. (C) 
In schizophrenia, the coordinated up-regulation of the dopamine receptors does not exist, or exists at a greatly reduced level. 454    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
COMT gene contains methylation sites that are actively 
regulated. Our experiments [2, 3] studied promoter methyla-
tion and gene expression levels in Brodmann Area 46 (DL-
PFC) of normal versus neuropsychiatric (schizophrenia and 
bipolar) individuals (Fig. 4). The results revealed a signifi-
cant correlation between membrane-bound COMT (MB-
COMT) promoter hypo-methylation (especially at SP1 bind-
ing sites) and over-expression of the MB-COMT gene pro-
duct in schizophrenia and bipolar disorder.  
  The same samples used above were genotyped for a 
common COMT allele (Val158Met single nucleotide poly-
morphism (SNP)). The results showed that schizophrenia 
samples were more likely to have a VAL allele, and less 
likely to be homozygous for the MET allele than controls. 
Bipolar patients were more likely to be homozygous for the 
VAL allele than controls.  
  The Val158Met polymorphism is known to directly af-
fect the thermostability of the MB-COMT protein. The Met 
alleles is thermolabile, causing COMT enzyme activity in 
Met homozygotes to drop to approximately 1/3 the level of 
Val homozygotes at physiological temperature [53]. COMT 
hyperactivity (from the Val allele) has been linked to poor 
working memory as well as disturbed executive function and 
attention [54-58]. Genetic epigenetic gene expression results 
showed that dopamine degradation in the synaptic cleft is 
increased in individuals with schizophrenia because of in-
creased COMT activity or expression. 
  Additional studies examined the expression and regula-
tion of other genes involved in dopamine metabolism. The 
results revealed that expression of the dopamine receptor 1 
(DRD1) was inversely correlated with MB-COMT expres-
sion in all groups, although to a lower level in the patient 
groups. DRD2 showed the reverse pattern: hypo-methylation 
of the MB-COMT promoter was nearly always associated 
with hypo-methylation of the DRD2 promoter and higher 
DRD2 gene expression levels. However, schizophrenia and 
bipolar patients show a significantly less severe decrease in 
methylation of their DRD2 promoters in response to MB-
COMT hypo-methylation.  
  Also, the promoter methylation state of the RELN gene 
was significantly linked to Val158Met genotype. All schizo-
phrenics and control subjects possessing a Val/Val genotype 
had a hyper-methylated RELN promoter and a decrease in 
RELN gene expression. This is consistent with results [59, 
60] that hyper-methylation of the RELN promoter and sub-
sequent low expression of the reelin gene in the frontal lobes 
is correlated with schizophrenia.  
  The fact that control subjects more strongly downregulate 
DRD1 expression and upregulate DRD2 expression when 
they possess a hypo-methylated MB-COMT promoter sug-
gests that a mechanism exists for regulation of synaptic do-
pamine at the transcriptional level. Coordinated regulation 
was absent or decreased in neuropsychiatric patients. More 
recent unpublished data has detected aberrant methylation of 
the DAT1 and DRD4 promoters, but not the NRG1, HTR2A 
or NOS1 promoters, in samples from schizophrenic brains 
versus control subjects. The results suggest that aberrant 
synaptic dopamine metabolism in the schizophrenia/bipolar 
brain through genetic or epigenetic causes may contribute to 
disease pathogenesis. 
  Other groups have also examined methylation deficits in 
schizophrenia. For example, the methyltransferase DNMT1is 
up-regulated in the inhibitory inter-neurons of schizophrenia 
patients (reviewed in [61]). DNMT1 up-regulation is sug-
gested to induce hyper-methylation and down-regulation of 
RELN and the GABA synthesizing enzyme GAD67 in pre-
frontal inter-neurons of schizophrenia patients. Woo et al. 
[62] and Costa et al. [61] speculated that down-regulation of 
the NMDA receptor subunit NR2A in these neurons may 
stem from hyper-methylation after DNMT1 up-regulation. 
RELN controls the surface expression of two other NMDA 
receptor subunits (NR2B and NR1, [63]) suggesting a possi-
ble deficit in NMDA receptors in the inter-neurons of 
schizophrenics. This supports the “NMDA hypofunction 
theory of schizophrenia” developed from observations that 
NMDA receptor antagonists, PCP and ketamine, both induce 
schizophrenia-like symptoms. In addition, the SOX10 (sex-
determining region Y-box containing gene 10) gene, an oli-
godendrocyte specific transciption factor with a large CpG 
promoter island, is hyper-methylated and down-regulated in 
the prefrontal cortex (BA10) of schizophrenia patients [64]. 
GENOMIC INSTABILITY 
  Our initial research on schizophrenia focused on 
monozygotic twins. The goal was to understand disease dis-
cordance: how does one monozygotic twin avoid illness, and 
how do both the ill and well twin passed the same elevated 
genetic predisposition to progeny [1]. The specific aim was 
to identify, clone and sequence the expected small number of 
somatic changes present in monozygotic twins discordant for 
disease, and then do further studies to determine whether any 
differences were related to disease occurrence/presentation. 
The research targeted anonymous (CAG)n because these se-
quences are unstable and located within a number of genes 
linked to schizophrenia (e.g. [65-67], Fig. 5). The experi-
ments examined anonymous restriction length polymorphism 
(RFLPs) of PCR amplicons containing (CAG)n repeating and 
adjacent sequences in lymphocytes using a method devel-
oped by us called Targeted  Genomic  Differential  Display 
(TGDD) [68]. TGDD is similar to differential display [69], 
but examines subsets of DNA sequences sharing a targeted 
sequence. 
  Unexpectedly, a statistically significant high level of 
RFLP variability around (CAG)n was detected in monozy-
gotic twins discordant for schizophrenia (Fig. 6). Twin pairs 
concordant for the disease had greater variability than con-
trols, but for this small sample size this variability did not 
reach statistical significance. Assuming all the twin pairs 
were monozygotic (i. e., began life with identical DNA), 
RFLP variability must reflect somatic mutation rates after 
twinning. Hence, the results showed that a high somatic mu-
tation rate was associated with schizophrenia, especially in 
monozygotic twins discordant for disease.  
  Evidence supporting the idea include that schizophrenia 
is linked to genome instability. Cytogenetic observations of 
increased chromosome aneuploidy in brain cells from indi-
viduals with schizophrenia [70, 71] and other neurological 
diseases including autism, ataxia-telangiectasia [72, 73], 
Alzheimer's disease [72], Down syndrome, Edwards syn-
drome, Patau syndrome, Parkinson's disease, spinal muscular Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    455 
atrophy, mental retardation, Turner syndrome, psychiatric 
disorders associated with trisome X and Klinefleter syn-
drome, and 47,XYY karyotype (reviewed in [74- 
77]). Other evidence (reviewed in [1]) is the skewed (CAG)n 
repeat distribution in schizophrenia (Fig. 5), and the inverse 
correlation of disease with some cancer (reviewed in [78]). 
  More recently, genome wide scanning of SNPs in asso-
ciation studies revealed an elevated rate of copy number 
variation (CNV) in schizophrenia [79-82], and a number of 
other neuropsychiatric diseases such as autism, mental retar-
dation, bipolar disease, Rett syndrome, Tourette’s syndrome, 
Prader-Willi/Angelman syndrome etc. (e.g. [18, 83], for re-
view see [84]). Clearly, genomic instability is linked to neu-
rological disease. 
FRAGILE SITES 
  Fragile sites are regions of the genome that are prone to 
mutation and epigenetic changes; hence, hot spots for ge-
nomic instability. A fragile site is defined as unstable DNA 
stretch that appears as a gap or break on metaphase chromo-
somes (Fig. 7A) when DNA replication of dividing cells is 
partially inhibited by incubation in culture medium deficient 
in folic acid or containing Bromodeoxyuridine (BrdU), dis-
tamycin, 5 azacytidine, or aphidicolin [85, 86].  
  Fragile sites are unusual chromosomal abnormalities be-
cause, although heritable, they appear only in a subset of 
cells, and usually only occur when induced. There are 119 
known fragile sites (Tables 1 and 2), spread throughout the 
genome classified as common or rare based on frequency in 
the population (greater or less than 5%, respectively).  
  The first identified and best studied example of the asso-
ciation between fragile sites and mental illness is Fragile X 
syndrome. Fragile X syndrome is associated with transcrip-
tional silencing of either FMR1 or FMR2 (Fragile X mental 
retardation genes 1 and 2) on chromosome X (for review see 
[87]). Silencing of FMR1 or FMR2 is accompanied by hy-
per-methylation of the (CGG)n expansion within fragile sites 
FRAXA at Xq27.3 or FRAXE at Xq28, respectively. The 
number and methylation status of the (CCG)n repeating se-
quences influences the expression of the fragile X mental 
retardation genes. The FRAXA and FRAXE promoter sites 
behave similarly. For FRAXA sites, well individuals have 7 
to 50 (CCG)n repeating sequences (with a mode of 30). Men-
tal retardation occurs, and the fragile site becomes visible 
under folate deficient conditions, when the repeat number 
exceeds 230 and becomes hyper-methylated. Repeat num-
bers can reach up to 2000. Numbers between 50 and 200 are 
un-methylated and considered “pre-mutations”, but carriers 
may have symptoms other than mental retardation [88]. 
Schizophrenia is linked to several fragile sites (Table 4), 
some of which are unique (e.g. [89]). Neurological diseases 
and cancers [90, 91] are linked to specific sites as well   
(Table 3).  
  Cells from schizophrenia patients grown in the absence 
of folate present a greater overall number of fragile sites per 
metaphase than controls [92, 93]. These results may indicate 
that schizophrenia patients may have a greater sensitivity to 
folic acid deficiency, or a higher number of fragile sites with 
borderline expansion (e. g. see (CAG)n repeats in schizo-
phrenia above).  
  Most fragile sites are mapped only to the low-resolution 
chromosomal cytogenetic band level; ~15 fragile sites are 
characterized at the sequence level. One site appears to be ~3 
million base pairs (bp) in size and contains 10 genes and 
multiple repeat sequences. Rare folate sensitive sites like 
FRAXA are composed of the expanded simple trinucleotide 
repeat (CCG)n while some contain other interspersed repeats 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Trinucleotide repeat distribution in individuals with 
schizophrenia.  Genes having (CAG)n and (CCG)n repeating se-
quences have been linked to specific diseases and to schizophrenia. 
The specific disease mutations are typical of repeat diseases where 
a repeat number over a threshold value (~50 repeats) leads to dis-
ease. Black = Distribution in unaffected individuals. Grey = In 
schizophrenia individuals, the repeat distribution is skewed towards 
larger sizes but not greater than the threshold value linked to spe-
cific disease.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Somatic genomic instability in twins affected by 
schizophrenia.  TGDD was used for RFLP analysis of genomic 
fragments containing (CAG)n repeats and adjacent sequence in 12 
pairs of monozygotic twins. The results showed that twins concor-
dantly well or concordantly affected by schizophrenia had fewer 
differences than twins discordantly affected by schizophrenia. As-
suming these twins began life as with identical DNA (i.e. are 
monozygotic), the observed differences represent somatic muta-
tions, and the results show a higher somatic mutation rate in twins 
discordantly affected by schizophrenia. 456    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
(e.g. LINE) or AT-rich sequences (e. g. common fragile sites 
are linked to AT-rich sequences). Replication of repeating 
sequences, or any sequence that deviates from the mean G+C 
level, can stress metabolism because the DNA replication 
machinery requires a different ratio of deoxynucleoside 
triphosphates (i. e. the ratio of G+C vs A+T).  
  We calculated that ~70% of the human genome was de-
void of fragile sites by determining what percent of the ge-
nome, at the cytogenetic band level, was linked to one or 
more fragile sites (Fig. 7B). Our preliminary analysis [1] 
using chromosome abnormalities and genes linked to 
schizophrenia (reported in [94] and [95], respectively) found 
that ~70%, rather than the expected ~30% (X^2, p = 0.001), 
co-localize to regions of the having fragile sites.  
  More recent studies by us reviewed 387 genetic studies 
from the literature that identified 111 unique genes linked to 
schizophrenia (Fig. 8). Of the 111 genes, 58 co-localized 
with at least one fragile site at the Giemsa band level (df = 1, 

2=14.227, p <0 .0001; Odds Ratio = 2.92). Moreover, a sig-
nificant number of rare (CCG)n containing fragile sites co-
localized with the sample of genes (df = 1, 
2=5.67, p < .025; 
Odds Ratio = 2.285). More detailed and updated information 
will be provided elsewhere.  
  Expansion of repeating sequences within fragile sites is 
accompanied by local hyper-methylation (i.e. FRAXA and 
FRAXE) and the appearance of fragile sites in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Fragile site appearance and distribution. A. Cytogenetic appearance of fragile X. Arrows point to fragile sites. B. Distributation 
of fragile sites along chromosome 1. The bars beside the cytogenetic bands represent the fragile site locations (see Table 1). Dark to light 
bars represent inducing agents. Amphidicolin, 5-Azacytidine, and Folic acid, respectively. Taken from [150]. 
Table  2.  Summary of Fragile Sites within the Human   
Genome 
Inducer Common  Rare  Total 
Folic 78  22  100 
Amphidicolin 78  0  78 
BrdU 7  2 9 
5-AzaC 4 0  4 
Distamycin 0  5  5 
Unclassified 1  0  1 Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    457 
Table 3.  Neurological Diseases Associated with Specific Fragile Sites. Gene Names for Abbreviations are Shown in Table 4 
Fragile Site  Associated Gene(s)  Neurological Disease 
FRA2A   Mental  retardation/schizophrenia 
FRA2B   Autism 
FRA4F GRID2  Tremor/Ataxia 
FRA6A   Autism 
FRA6E  PARK2  Autosomal Juvenile Parkinsonism 
FRA6F LAMA4  Schizophrenia 
FRA7I CNTAP2  Tourette's   
FRA9F   Schizophrenia 
FRA11B CBL2  Jacobsen's  Syndrome 
FRA12A  DIP2B  Autism / Mental retardation 
FRA13A NBEA  Sporadic  Autism 
FRA15A RORA  Tremor/Ataxia,  Imbalance 
FRAXA  FMR1  Fragile X Mental Retardation / FRAXA Tremor Ataxia 
FRAXC  IL1RAPL1, DMD  Mental Retardation associated with complex glycerol kinase deficiency 
FRAXE  FMR2  Fragile X Mental Retardation (mild) 
Global FS Expression  ATR  Seckel syndrome 
 
Table 4.  Summary of Genes Linked to Schizophrenia and Fragile Sites 
GENE FRAGILE 
NAME ALIAS  FUNCTION  ADDRESS  SITE  ADDRESS 
CHROMOSOME 1 
GSTM1       glutathione S-transferase M1  1p13.3       
GRIK3      glutamate receptor ionotropic  1p34-p33       
HTR6      5-hydroxytryptamine (serotonin receptor type 6)  1p36-p35 FRA1A 1p36 
RHD      Rhesus blood group D antigen  1p36.11 FRA1A 1p36 
MTHFR      5 10-methylenetetrahydrofolate  1p36.3  FRA1A  1p36 
SCZD9      schizophrenia disorer 9  1q21-q22 FRA1F 1q21 
SYT11      Synaptotagamin X1  1q21.2 FRA1F  1q21 
KCNN3  hSKCa3   potassium intermediate/small c  1q21.3 FRA1F  1q21 
RGS4     regulator: g-protein signaling 4  1q23.2       
 IL10      interleukin 10  1q31-q32 FRA1K 1q31 
DISC2      disrupted in schizophrenia 2  1q32.1       
DISC1      disrupted in schizophrenia 1  1q42.1 FRA1H  1q42 
CHROMOSOME 2 
NOGO  RTN4 reticulon  4  2p13-p14  FRA2E  2p13 
IL1B     interleukin 1 beta  2q14       
NR4A2    
nuclear receptor subfamily 4, group A, member 
2 
2q22-23 FRA2K  2q22.3 
CTLA4      cytotoxic T-lymphocyte-associative protein  2q33 FRA2I  2q33 458    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
(Table 4). Contd….. 
GENE FRAGILE 
NAME ALIAS  FUNCTION  ADDRESS  SITE  ADDRESS 
CHROMOSOME 3 
GRM2  GRM2  glutamate receptor metabotropic 2  3p21.31       
 CCK      cholecystokinin  3p22-p21.3       
GRM7  GRM7  glutamate receptor metabotropic 7  3p26.1-p25.1       
CHL1 CALL    
cell-adhesion molecule with homology to 
L1CAM 
3p26.1       
DRD3      dopamine receptor D3   3q13.3       
CHROMOSOME 4 
GABRB1  GABRB1  gamma-aminobutyric acid (GABA) receptor, 
beta 1 
4p12       
CCKAR       cholecystokinin A receptor  4p15.1-p15.2 FRA4D  4p15 
DRD5      dopamine receptor D5  4p16.1 FRA4A  4p16.1 
CHROMOSOME 5 
GDNF      glial cell derived neurotrophic factor  5p13.1-p12 FRA5A  5p13 
SCZD1      schizophrenia disorder 1  5q11.2-q13.3       
Homer 1       homer homolog 1 (Drosoph)  5q14.2       
HTR4      5-hydroxytryptamine (serotonin) receptor 4  5q31-q33.2 FRA5C 5q31.1 
GABRB2     GABA A receptor, beta 2  5q34       
H2 rec  HRH2   histamine H2 receptor  5q35.3  FRA5G  5q35 
DRD1     dopamine receptor D1  5q35.1  FRA5G  5q35 
CHROMOSOME 6 
NQO2     NADPH hydrogenase quinone 2  6pter-q12 FRA6C/A/B  6p22.2/23/25.1 
NOTCH4      Notch homolog 4 (Drosophila)  6p21.3       
TNFA     Tumor necrosis factor alpha  6p21.31       
HLA  HLA-A  major histocompatability complex , class I, A  6p21.3       
TNXB     tenascin XB  6p21.3       
DTNBP1     dystrobrevin binding protein 1  6p22.3       
SCZD3     schizophrenia disorder 3  6p23 FRA6A  6p23 
SCA1      spinocerebellar ataxia 1 (oliv)  6p23 FRA6A  6p23 
CB1  CNR1   Cannabinoid receptor 1   6q14-q15 FRA6G 6q15 
SCZD5     schizophrenia disorder 5  6q13-q26 FRA6D/E  6q13,q26 
HTR1B      5-hydroxytryptamine (serotonin) receptor 1B  6q13 FRA6D  6q13 
Fyn kinase  FYN   FYN oncogene related to SRC, FGR, YES  6q21 FRA6F  6q21 
CHROMOSOME 7 
DDC  DDC   dopa decarboxylase (aromatic L-amino acid 
decarboxylase) 
 7p11  FRA7A  7p11.2 
NPY     Neuropeptide Y  7p15.1       
GRM3      glutamate receptor metabotropi fact. 3   7q21.1-q21.2  FRA7E  7q21.2 
RELN      reelin   7q22  FRA7F  7q22 
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(Table 4). Contd….. 
GENE FRAGILE 
NAME ALIAS  FUNCTION  ADDRESS  SITE  ADDRESS 
CHROMOSOME 8 
NRG1      neuregulin 1  8p21-p12       
SCZD6     schizophrenia disorder 6  8p21       
PPP3CC     protein phosphotase 3  8p21.2       
FDZ3     frizzled homolog 3  8p21       
DPYSL2     human dihydroppyrimidinase-related protein 2  8p21-p22       
CHROMOSOME 9 
OPRS1  OPRS1  opioid receptor, sigma 1  9p13.2       
DBH     dopamine beta-hydroxylase (dop)  9q34       
GRIN1  NMDA  glutamate receptor ionotropic  9q34.3       
CHROMOSOME 10 
SCA8     spinocerebellar axia protein 8  10q23.3-24.1  FRA10A  10q23.3 
VMAT2  SVMT  solute carrier family 18 (vesicular monoamine), 
member 2 
10q25  FRA10B/E  10q25.2 
CHROMOSOME 11 
PAX6      paired box gene 6 (aniridia k)  11p13 FRA11E  11p13 
BDNF      brain-derived neurotrophic fac  11p13 FRA11E  11p13 
TPH1      tryptophan hydroxylase   11p15.3-p14 FRA11D  11p14.2 
TH      tyrosine hydroxylase  11p15.5       
cPLA2  HTATIP2  HIV-1 Tat Interactive Protein 60kDa  11q13 FRA11A/H  11q13.3/  13 
GRIA4      glutamate receptor ionotrophi  11q22       
DRD2      Dopamine receptor D2  11q23 FRA11B/G  11q23.3 
HMBS      hydroxymethylbilane synthase  11q23.3 FRA11B/G  11q23.3 
B3GAT     beta-1, 3-Glucronyltransferase-1  11q25       
CHROMOSOME 12 
NR2B  GRIN2B  glutamate receptor, ionotropic, N-methyl D-
aspartate 2B 
12p12       
NTF3  NT3  neurotrophin 3  12p13       
B37  DRPLA  dentatarubral-pallidoluysian atrophy (atrophin- 
1) 
12p13.31       
PAH     phenylalanine hydroxlase   12q22-24.2  FRA12C/E/D 12q24/24.13 
PLA2      phospholipase A2. group IB   12q23-q24.1  FRA12C/E/D 12q24/24.13 
NOS1      nitric oxide synthase 1 (neuro)  12q24.2-q24.31 FRA12C/E  12q24 
DAO  DAOA  d-amino acid oxidase  12q24 FRA12C/E/D  12q24/24.13 
CHROMOSOME 13 
CAGR1 ***     mab21-like 1 (c. elegans)  13q13 FRA13A  13q13.2 
HTR2  HTR2/ HTR2a  5-hydorxytryptamine (serotonin) receptor  13q14-q21 FRA13B/C  13q21-q21.2 
SCZD7     schizophrenia disorder 7  13q32  FRA13D  13q32 
G72  DAOA  d-amino acid oxidase activator  13q34       460    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
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GENE FRAGILE 
NAME ALIAS  FUNCTION  ADDRESS  SITE  ADDRESS 
CHROMOSOME14 
NPAS3     neuronal pas domain protein 3  14q12-q13       
CHROMOSOME 15          
HERC2     hect doman and RLD2  15q13       
CHRNA7      cholinergic receptor nicotini  15q14       
SCZD10     schizophrenia disorder 10  15q15       
CHROMOSOME16 
GRIN2A     glutamate receptor, ionotropic 2A  16p13.2       
CHROMOSOME 17 
SLC6A4  SLC6A4  serotonin transporter  17q11.2-q12       
 ACE       angiotensin I converting enzym  17q23 FRA17B  17q23.1 
CHROMOSOME 18 
IMPA2     inositol(myo)-1(or 4)-monophos  18p11.2       
CHROMOSOME 19 
SCA6  CACNA1A 
 calcium channel, voltage dependent, P/Q type, 
alpha 1A subunit 
19p13.2-p13.1 FRA19B  19p13 
APOE      apolipoprotein E  19q13.2  FRA19A  19q13 
DNMT     DNA methyltrasnferase 1  19q13.2  FRA19A  19q13 
CHROMOSOME 20 
PRNP     prion protein (p27-30) (Creutz)  20pter-p12 FRA20B 20p12.2 
SNAP-25     synaptosomal-associated protein 25kDa  20p12-p11.2  FRA20B/A  20p12.2/11.23 
CHGB     chromogranin B ( secretogranin 1)   20pter-p12  FRA20B  20p12.2 
CHROMOSOME 22 
COMT      catechol-O-methyltransferase  22q11.21       
SNAP29      synaptosomal-associated protein  22q11.21       
PCQAP     PC2 (positive cofactor 2 mult  22q11.2       
PRODH/DGCR6     DiGeorge Syndrome critical region, gene 6  22q11.21       
UFD1L      ubiquitin fusion degradation 1  22q11.21       
ZNF74      zinc finger protein 74 (Cos52)  22q11.21       
APOL-4     apolipoprotien L-4  22q11.2-13.2  FRA22A/B 22q12.2/13 
APOL-2     apolipoprotien L2  22q12  FRA22B 22q12.2 
SYN3     synaptin 3  22q12.3       
 TIMP3      tissue inhibitor of metalloprot.3  22q12.3       
YWHAH      tyrosine 3-monooxygenase/trypt  22q12.3       
APOL-1     apolipoprotein L1  22q13.1  FRA22A 22q13 
SYNGR1     synaptogyrin 1  22q13.1  FRA22A 22q13 
CYP2D6      cytochrome P450 family 2 sub  22q13.1 FRA22A  22q13 Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    461 
(Table 4). Contd….. 
GENE FRAGILE 
NAME ALIAS  FUNCTION  ADDRESS  SITE  ADDRESS 
IL2RB     interleukin 2 receptor beta   22q13/13.1 FRA22A  22q13 
BZRP  BZRP  benzodiazapine receptor (peripheral)  22q13.31 FRA22A 22q13 
WKL1  MLC1 
megalencephalic leukoencephalopathy with 
subcortical cysts 1  
22q13.33  FRA22A  22q13 
X CHROMOSOME 
HTR2C     5-hydorxytryptamine (serotonin) receptor 2C  Xq24       
 L1CAM      L1 cell adhesion molecule    Xq28  FRAXE/F  Xq28 
Studies were obtained from the National Institute of Health’s database linking specific genes to schizophrenia at http://www.geneticassociationdb.com. In addition, a Pubmed search 
using the keywords "gene AND schizophrenia" yielded more unique studies. The genes found using these two methods were then searched more exclusively using the keywords “ 
gene name” AND schizophrenia” in order to more thoroughly assess whether at least one positive association was found between a gene and schizophrenia. Genes are organized by 
chromosomal locations, and appear in bold when co-localizing with a chromosomal fragile sites. The co-localizing fragile site name and address is shown. More information can be 
found at http://schizogad.bu.edu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Genomic distribution of genes, chromosomal regions, 
and chromosomal abnormalities linked to schizophrenia vs 
fragile sites. These results were obtained by cataloguing genes 
linked to schizophrenia from a Pubmed search 
(http://www.ncbi.nlm.nih.gov) using the words "schizophrenia" 
AND "genes", "genetic studies", or "chromosomal abnormalities". 
The genomic regions that contain a fragile site was determined 
from a Pubmed search using the words "fragile sites". The genome 
"real-estate" of each locus and all the fragile sites was taken as the 
highest known chromosome banding resolution. Negative controls 
consisting of (a) all human genes and (b) genes tested but not found 
to be associated with schizophrenia did not have any preferential 
association with fragile sites.  
Certainly, genes in fragile sites regions in the brain may be 
impacted in vivo when individuals are folate malnourished 
during development. In adults, DNA replication in the brain 
occurs in the dentate gyrus and olfactory bulb, hence folate 
deprivation could impact neurogenesis during all periods of 
life, perhaps transiently increasing the severity of disease.  
  In summary, fragile sites are more frequent in schizo-
phrenia and co-localize with schizophrenia-linked genes. 
Fragile sites are sensitive to conditions that interfere with 
DNA replication, including folate deficiencies. Schizophre-
nia is linked to folate metabolism genetically (e. g. through 
hypoactive polymorphisms in genes that directly affect folate 
processing (e. g. MTHFR, MTR – see meta-analysis in [96])) 
and through epigenetic studies (see above) and environ-
mental studies (see below).  
ENVIRONMENTAL FACTORS AND SCHIZOPHRE-
NIA 
  Some environmental factors linked to schizophrenia dur-
ing early development are listed in Table 5. No factor is suf-
ficient by itself to induce disease. Family history, CNS dam-
age, bereavement, and rubella infection increase the odds 
ratio most for disease. Paternal age and nutrition, well-
documented factors linked to schizophrenia, provide impor-
tant clues for understanding the biochemistry of schizophre-
nia. Further, the metabolic links can be used to postulate a 
role for other environmental components in disease (see be-
low).  
Paternal Age 
  Since 1958, many studies have implicated paternal age as 
an environmental factor influencing the occurrence of 
schizophrenia (e. g. [97-99]). For instance, Malespina et al. 
[97] reported a three-fold increase in the incidence of 
schizophrenia in progeny of fathers over the age of 50 years 
(Fig. 9). Today, the association with maternal age is unclear. 
Paternal and maternal age are linked to autism [100]. 
  The paternal age connection implicates changes to pater-
nal germline DNA in some cases of schizophrenia because 
DNA is the sole paternal biological contribution to progeny. 
Paternal aging is linked to diminished semen quality [101] 
and fertility [102], increases in sperm DNA damage (e.g. 
[103-105]) spontaneous abortions [105, 106], birth defects 
[106, 107] and singe base changes in rare autosomal domi-
nant diseases [108-110]. For instance, mutations in DF1 fi-
broblast growth factor receptor (FGFR3) are linked to 
Achondroplasia. Mutations in FGF2 are linked to Apert, 
Crouzon, and Pfeiffer syndrome (PS), although some PS 
mutations may occur in FGFR2. Mutations in the lamina A 462    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
(LMNA) gene are linked to Progeria, while mutations in 
REarranged during transfection (RET) are linked to multiple 
endocrine neoplasia (MEN2A MEN2B) and medullary thy-
roid carcinoma (MTC).  
  Base substitutions account for all but progeria mutations 
in LMNA. The majority of mutations are transitions, (C to T) 
although some transversions (C to G) occur in a single 
dinucleotide CpG sequence. However, neither the number of 
replication cycles nor the observed mutation rates [110-113] 
accounts for the exponential rather than linear increase in 
disease as a function age; hence, it was suggested that these 
mutations confer a selection growth advantage to sperm. 
Lower and more linear-like increases as a function of pater-
nal age are observed for a number of other rare autosomal 
dominant diseases such as neurobromatosis, bilateral retino-
blastoma, Treacher Collins syndrome, multiple extostoses, 
and Sotos syndrome [108, 112, 113], as well as Down syn-
drome, neural tube defects, congenital cataracts, and reduc-
tion defects of the upper limb [105, 107]. 
Nutrition 
  Under-nutrition (general caloric or protein deficiency) 
and malnutrition (deficiencies in specific elements, e. g. folic 
acid, zinc, copper, etc.) occur worldwide and are the most 
common diseases of childhood and prenatal life. Moderate to 
severe under-nutrition occurring prior to 2 years of age is 
associated with persistent behavioral and cognitive deficits 
that resist nutritional rehabilitation [114]. Pregnant mothers 
exposed to famine [115, 116] or malnourished (e.g. for folate 
deficiencies [117]) have an increased risk for children with 
schizophrenia. Maternal exposure to nutritional insults leads 
to persistent physiological and biochemical effects on the 
offspring [118-121]. Nutritional, factors that have been 
linked to schizophrenia and autism, like folate deficiency, 
can impact both genetics (DNA damage and fragile site ex-
pression) and epigenetics (DNA methylation via folate defi-
ciency) in affected individuals. Generally, the specific 
mechanism(s) by which nutritional deficiencies produce 
these birth defects are unknown. 
Folic Acid 
  The importance of folic acid in preventing birth defects 
(e.g. neural tube defects including spina bifida) is well 
known, although the mechanism of disease induction is not 
understood [122]. Less well known is that fact that folic acid 
deficiencies are associated with a number of neurological 
diseases (e. g. [123, 124]) including schizophrenia and mood 
disorders [125-129], and are common in patients with psy-
chopathology [130]. Furthermore, genes specifying proteins 
involved in folate metabolism are associated with schizo-
phrenia and mood disorders as well as autism and other neu-
ropsychiatric diseases [131]. Folic acid provides methyl 
groups to form S-adenosyl-methionine (SAM, see below), 
the universal intracellular methyl donor during methylation 
reactions such as those important in epigenetics. 
Folic Acid Metabolism 
  At the molecular level, folic acid deficiencies have the 
potential to disrupt nucleic acid metabolism, processes that 
require energy (i.e. ATP or NAD, GTP), activated nucleotide 
precursors (ribo - and deoxyribo- nucleoside triphosphates, 
e. g. DNA replication and RNA transcription), or SAM (or 
folate directly) for methylation (Fig. 10). Abbreviated 
schemes of de novo synthetic pathways for ribo- and deoxy-
ribo- nucleoside triphosphate synthesis are shown in Fig. 
(11). Folate derivatives are required by thymidine synthase 
Table 5. Odds Ratio of Genetics and Environmental Factors 
Linked to Schizophrenia. Adapted from [149] 
Factor   Odds  Ratio 
Winter 1.2  Place/time of birth 
Urban 1.5 
Influenza 2.0 
Respiratory 2.2 
Rubella 5.2 
Poliovirus 1.1 
Infection 
CNS 4.0 
Famine 2.0 
Bereavement 6.2 
Flood 1.8 
Unwantedness 2.4 
Prenatal 
Maternal depr  1.8 
Rh incompatibility  2.8 
Hypoxia 3.0 
CNS damage  7.0 
Low birth weight  1.6 
Obstetric 
Pre-eclampsia 2.5 
Genetics Family  history 9.7 
 
 
 
 
 
 
 
 
 
 
Fig. (9). The effect of paternal age on schizophrenia. The data 
shows a linear increase in the incidence of schizophrenia and pater-
nal age, and a three-fold increase for children of fathers over the 
age of 50. Figure is adapted from [97]. Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    463 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Folic Acid Cycle. Folate is an essential nutrient that is required in the synthesis of nucleic acid, s-adenosyl methionine (SAM) and 
amino acids. Further, synthesis of these monomers and their incorporation into polymeric molecules most times requires activated nucleosides 
like ATP, NAD and GTP whose synthesis depends on folic acid intermediates. Hence, the synthesis of DNA/RNA and SAM is heavily de-
pendent on folic acid. (Figure adapted from http://www.tcd.ied/ IUBMB-Nicholson/pdf/29.pdf). 
                  A         B  
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). Abbreviated schematic of metabolic pathways leading to the de novo biosynthesis of RNA and DNA precursors. Purines are 
synthesized from a branchpoint intermediate, inosine monophosphate (IMP). In the primidine pathway, deoxyuridine and deoxythymidine 
intermedates are made from deoxycytidine diposphate. ATP, is predominantly synthesized from ADP in the mitochondria, and is the most 
used cofactor in the cell. Deoxynucleotides are made from ribonucleotides. 
that converts dUMP to dTMP, and for two steps in the purine 
biosynthetic pathway to make IMP; hence impacting ribo 
and deoxyribo purine synthesis.  
  Folate participates in the methioine cycle to synthesize S-
adenosyl methionine (SAM). SAM is the second most used 
cofactor in the cells after ATP (Fig. 12). SAM is used by 
>100 methyl transferases that act on DNA, RNA, proteins  
(e. g. DNA methyl transferase DNMT (for review see [40])), 
histone methyl transferases (HMT), and small molecules 
(e.g. COMT), and for the synthesis of polyamines that stabi-
lize DNA.  
  In the methionine cycle, a methyl group from folate is 
use by the enzyme, Methionine Synthase (MS), to convert 
homocysteine (HCY) to methionine. Alternatively, Betaine 464    Current Genomics, 2010, Vol. 11, No. 6  Smith et al. 
Homocysteine Methyl Transferase (BHMT) regenerates me-
thionine from HCY using a methyl group from betaine (cho-
line). Dietary and regenerated methionine reacts with ATP to 
generate SAM, while HCY is the product of de-methylated 
(via methyl transferases) and de-adenylated SAM. 
  Besides being used to reform methionine, HCY may be 
directed towards the trans-sulfuration pathway to produce 
the amino acid cysteine, and the primary intracellular anti-
oxidant, glutathionine (GSH) HCY is up-regulated in 
schizophrenia patients with a 5 microM plasma HCY level 
associated with a ~1.7 fold increase in schizophrenia risk 
[95].  
  MS, the enzyme that uses folate to reform methionine   
from HCY, covalently adds a folate derived methyl group to  
the dopamine D4 receptor. The dopamine D4 receptor acts  
like a methyl transferase when activated by dopamine and  
transfers the methyl group to membrane lipid polysaccha- 
ride, changing local membrane fluidity [131]. Dopamine   
function and metabolism is therefore tied to the folate- 
methionine-transulfuration metabolic hub in multiple ways:  
directly, through dopamine degradation by COMT, and indi- 
rectly through dopamine D4 receptor methyl transferase ac- 
tivity and promoter methylation of genes active in dopamine  
metabolism in the synaptic cleft.  This metabolic hub (Fig.  
12) links DNA replication and epigenetic changes through  
folate and SAM metabolism, and because epigenetic mark- 
ing closely follows DNA replication at the macromolecular  
level. HCY, a key intermediate used for SAM metabolism, is  
required for the synthesis of GSH; hence, dopamine metabo- 
lism, DNA replication and epigenetic marking are linked to  
oxidative stress. 
  The brain is especially sensitive to oxidative stress. 
Oxidative stress (hypoxia) is linked to schizophrenia directly 
(Fig.  9), is a common consequence of obstetric complica-
tions linked to schizophrenia [132], and a potent inducer of 
fragile sites and genomic rearrangements [133]. Hence, oxi-
dative stress through the transulfuration pathway is linked to 
DNA metabolism, and epigenetic marking. For instance, 
increased oxidative stress can direct HCY toward GSH pro-
duction rather than SAM production, impacting many proc-
esses in vivo.  
  Nutrition is critical for maintaining the folate-
methionine-transulfuration hub because vitamines B6, B9 
(folate) and B12, and the amino acid methionine must be 
obtained from the diet. Other factors listed in Fig. (9) can 
impact the folate-methionine-transulfuration hub. For in-
stance, winter births are associated with times of food scar-
city [134], and many times bereavement and depression are 
accompanied by reduced food intact. Infection or inflamma-
tion increases metabolites requirements such as those needed 
for DNA replication, or transcription. 
  Aberrant folate metabolism in schizophrenia has been 
demonstrated in a number of studies, for review see [135, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). Confluence of the folate, methionine, trans-sulfuration, and dopamine D4 receptor methylation pathways. Folate is con-
verted to derivatives that are utilized for the synthesis of dTMP, and IMP, and the amino acids serine, glycine, methionine and glutamate. 
SAM is formed from methionine and adenosine in the methionine cycle. Homocysteine (HCY), a degradation product of SAM, is converted 
to methionine by the enzyme methionine synthase (MS), utilizing a folate derivative, or by betaine homocysteine methyl transferase (BHMT) 
utilizing betaine (a choline derivative) as a methyl donor. In addition, HCY is a precursor for the biosynthesis of cysteine and the primary 
intracellular antioxidant, glutathione (GSH). The enzyme MS covalently adds a methyl group to the dopamine D4 receptor (DRD4), which 
transfers the methyl group to lipopolysaccharides. In mammals, folate, methionine, and vitamins B6, B9 and B12 required by these path-
ways, must be obtained from the diet or intestinal bacteria. Methionine may also be obtained from degradation of proteins.  Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia  Current Genomics, 2010, Vol. 11, No. 6    465 
136, 2]. In fact, the Nobel Laureate (twice), chemist Linus 
Pauling, advocated for nutritional interventions in psychiatry 
in the 1960s [137].  
  Aberrant folate metabolism has been detected in autistic 
patients. In an impressive series of experiments, James et al. 
[138-141] detected aberrant levels of metabolic markers for 
the folate-methionine-transulfuration hub in patients and 
their mothers. For instance, decreased levels of methionine 
cycle (e.g. methionine, SAM, S-adenosylhomocysteine 
(SAH), adenosine, and HCY), and trans-sulfuration pathway 
(e. g. cystathionine, cysteine and total glutathione (oxidized 
(GSH) + reduced GSSG)), metabolites were detected. Also 
reported was an increase in other methionine cycle (e.g. 
SAM, adenosine) and transulfuration (e.g oxidized glu-
tathione) pathway metabolites. In 2006, James et al. [138] 
linked SNPs in genes within the folate cycle (in the reduced 
folate carrer (RFC), methylenetetrahydrofolate reductase 
(MTHR), the methionine cycle (COMT), and the transsul-
furation pathway (glutathionine-S-transferase (GST) to 
autism. In a preliminary study, James et al. [141] demon-
strated that a nutritional treatment regime (supplementation 
with methylcobalamine (methylated vitamin B6), and folic 
acid) improved but did not normalize abnormal metabolite 
blood values. An analysis of the effect of nutritional supple-
mentation on disease symptoms was not measured, although 
anecdotal improvements were reported. 
CONCLUSION 
  In summary, genetic and environmental components of 
schizophrenia and other neuropsychiatric diseases point to 
the importance of the folate-methionine-transulfuration 
pathway. This idea is exciting because this hub presents 
novel targets for drug development, and may lend them-
selves to nutrition interventions.  
  Folate supplementation has been successful in the pre-
vention of spina bifida and related abnormalities. Similar 
therapies may decrease risk and severity for neuropsychiatric 
disease. Faulty DNA replication and epigenetic marking dur-
ing brain development and adult neurogenesis may impact 
occurrence, presentation and dynamics of neuropsychiatric 
disease. Simply providing excess folate may not be useful 
(see [142]).  
  Reed and colleagues [143-146] have developed a dy-
namic model of the interaction of the folate and methionine 
cycles at the protein level. The Reed model is consistent with 
published data but does not yet include the entire folate-
methionine-transulfuration hub, nor has the model been 
tested experimentally. However, this model is a beginning, 
and reminds us that an understanding the complex, dynamic 
behaviors of metabolic pathways are required to developed 
individualized nutritional and/or medical interventions in 
patients.  
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